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Background: There are several methods to quantify mitral regurgitation (MR) by cardiovascular magnetic reso-
nance (CMR). The interoperability of these methods and their reproducibility remains undetermined.
Objective: Todetermine the agreement and reproducibility of differentMRquantificationmethods by CMRacross
all aetiologies.
Methods: Thirty-five patients with MR were recruited (primary MR= 12, secondary MR= 10 and MVR= 13).
Patients underwent CMR, including cines and four-dimensional flow (4D flow). Four methods were evaluated:
MRStandard (left ventricular stroke volume - aortic forwardflowbyphase contrast),MRLVRV (left ventricular stroke
volume - right ventricular stroke volume), MRJet (direct jet quantification by 4D flow) and MRMVAV (mitral for-
ward flow by 4D flow - aortic forward flow by 4D flow). For all cases and MR types, 520 MR volumes were re-
corded by these 4 methods for intra−/inter-observer tests.
Results: In primary MR, MRMVAV and MRLVRV were comparable to MRStandard (P > 0.05). MRJet resulted in signifi-
cantly higher MR volumeswhen compared toMRStandard (P< 0.05) In secondaryMR andMVR cases, all methods
were comparable. In intra-observer tests, MRMVAV demonstrated least bias with best limits of agreement (bias=
−0.1 ml,−8ml to 7.8 ml, P=0.9) and best concordance correlation coefficient (CCC= 0.96, P< 0.01). In inter-
observer tests, for primary MR and MVR, least bias and highest CCC were observed for MRMVAV. For secondary
MR, bias was lowest for MRJet (−0.1 ml, P_NS).
Conclusion: CMR methods of MR quantification demonstrate agreement in secondary MR and MVR. In primary
MR, thiswas not observed. Across all types ofMR,MRMVAV quantification demonstrated the highest reproducibil-
ity and consistency.
© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Mitral regurgitation (MR) is the secondmost common valvular heart
disease [1]. The quantification of MR volume categorically differentiates
between moderate to severe MR and hence is essential in its assess-
ment; both for conservative management and timing of surgical inter-
vention. Non-invasive imaging by echocardiography or cardiovascular
magnetic resonance (CMR) plays an important role in grading MR
severity [2].
CMR is established as the reference method for left ventricular volu-
metric assessment, and more recently, CMR methods of MR volume
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have shown to predict the timing of intervention and clinical outcomes
[3–5]. Overall, CMR provides complimentary clinical assessment when
compared to echocardiography [6,7]. There are several ways CMR can
quantify mitral regurgitant volume, including emerging techniques
which include direct MR jet volume quantification using four-
dimensional flow (4D flow) velocity encoded CMR imaging [7,8].
In clinical practice, it is routine to cross-checkMR volume quantifica-
tion between CMRmethods to increase confidence in the quantification
of MR volume and MR severity. However, the interoperability of these
methods remains undetermined. Furthermore, there is limited data on
intraobserver and interobserver reliability of different MR quantifica-
tionmethods [9]. A detailed understanding of the intermethod operabil-
ity and the reliability of each method will help clinical decision making
and also will be valuable in designing future prospective clinical studies
evaluating outcomes in mitral regurgitation.
Therefore, themain aims of this studywere to investigate the agree-
ment of different CMR methods to quantify MR and also assess the re-
producibility of each method in patients with primary MR, secondary
MR and also in patients who have hadmitral valve replacement (MVR).
2. Methods
2.1. Study population
This is a prospective study which recruited patients from two UK
centres with dedicated mitral valve services: Sheffield (n = 25) and
Leeds (n=10). Patients were identified in outpatient cardiology clinics
with an initial diagnosis of MR on echocardiography. Similarly, patients
with previous MVR were invited for a CMR study. Sheffield mainly re-
cruited primaryMR (n=12) and patientswithMVR (n=13). Leeds re-
cruited 10 patients with secondary MR.
The inclusion criteria included: age greater than 18, primary/second-
ary MR or previous MVR. The exclusion criteria included: patients with
valvular stenosis, shunts and contraindication to CMR.
2.2. Ethics
This study was approved by the National Research Ethics (17/LO/
0283 and 12/YH/0169) in the UK. Written informed consent was ob-
tained from all patients before participation. The study complied with
the Declaration of Helsinki.
2.3. CMR
At Sheffield, CMR was performed on a 3.0 Tesla Philips Healthcare
system (Achieva TX) equipped with a 28-channel coil and Philips
dStream digital broadband MR architecture technology. At Leeds, CMR
was performed on a similar 1.5 Tesla Philips Healthcare system
(Ingenia). Detailed description of CMR acquisition can be found in the
online supplementary file.
2.4. CMR protocol
The CMR protocol included a baseline survey, cines (vertical long
axis, horizontal long axis, short-axis contiguous left ventricle volume
stack, 3-chamber and aortic root) and 4D flow. Cines images were ac-
quired during end-expiratory breath-hold with a balanced steady-
state free precession, single-slice breath-hold sequence.
2.5. 4D flow acquisition
For the 4D flow acquisition, VENC setting was set at 150 cm/s. Field-
of-viewwas planned to cover the whole heart, including the aortic root.
The 4D flow sequence used echo-planar imaging acceleration factor of 5
with no respiratory gating. This sequence has been validated for
valvular flow quantification at both 1.5 T and 3 T field strengths
[10,11]. Other scan parameters were: acquired voxel size: 3x3x3mm,
reconstructed voxel size: 1.5 × 1.5 × 1.5mm, echo-time: 3.5 ms, repeti-
tion time: 10 ms, flip-angle 10°, the FOV 340 × 340 and 30 cardiac
phase. A sense factor of 2 in phase-encoding direction (Anterior-Poste-
rior) was applied. Partial k-space coverage in phase-encoding direction
was 90%. Arrhythmias rejectionwas used in caseswhere the 4Dflow ac-
quisitionwould halt due to R-R interval variability (occasional casewith
significant ventricular ectopic or atrial fibrillation). It was then in-
creased to 30% for R-R window variability.
Respiratory motion was monitored continuously by the radiogra-
pher performing the examination. Patients were requested to breathe
as consistently as possible throughout the three acquisitions. They
were given clear instructions not to fall asleep. Average time for 4D
flow acquisition was 8 ± 4 min. All 4D flow acquisitions were without
contrast.
2.6. 4D flow corrections
Data pre-processing was done on the scanner for correcting phase
offset errors such as eddy currents, Maxwell effects, and encoding errors
related to gradient field distortions. Quality checks were performed to
ensure that all imagesmet the standards needed for accurateflowquan-
tification. This included checking for slice shift artefacts, velocity aliasing
artefacts, and spatial misalignment between the cines and 4D flow
dataset. All three-phase directions were screened for aliasing artefact.
Particular attention was given to the region of interest: mitral valve
area while investigating for any aliasing artefact. If present, this was
manually corrected using established phase unwrapping methods [12].
2.7. Image analysis
Image analysis was done at Sheffield and Singapore. The analysis
was performed offline using the MASS software (version 2019 EXP,
LUMC, Netherlands). Ventricular volumes were segmented in the
short-axis cine stack as previously described [13,14].
2.8. Through-plane aortic flow
For quantification of the aortic forward flow, a fixed reformatted
plane was generated in established ways for the quantification of MR.
This was performed by generating a reformatted fixed through-plane
phase-contrast at the level of sino-tubular junction (STJ) in the ascend-
ing aorta. The plane was placed perpendicular to the vessel at the STJ.
We used this approach to minimise the overall time of acquisition,
and also our previous work demonstrates that two-dimensional
phase-contrast acquisition flow is comparable to 4Dflowquantified for-
ward flow through the aortic valve [10].
2.9. Retrospective valve tracking
On four-chamber cines, the mitral annular plane was identified for
the complete cardiac cycle. This plane was checked against the two-
chamber, and any angulations were corrected. After ensuring the
valve is properly tracked using this plane, we generated a phase-
contrast, valvular reformatted plane. On the reformatted valvular
plane, we segment the forward flow. Through-plane motion of the
valve plane was taken into account for the mitral valve.
2.10. MR quantification methods
Four CMR MR quantification methods were investigated in this
study. Fig. 1 and supplementary table 1 describe the MR quantification
methods investigated.
B. Fidock, G. Archer, N. Barker et al. International Journal of Cardiology xxx (xxxx) xxx
2
1. MRStandard (LVSV - AoPC)
This method involved the subtraction of the aortic (systolic) stroke
volume obtained by the above described reformatted aortic phase-
contrast (AoPC) plane through the sino-tubular junction from the left
ventricular stroke volume (LVSV) determined by endocardial segmen-
tation of the short-axis cine stack.
2. MRLVRV (LVSV - RVSV)
This method involved the subtraction of the right ventricular stroke
volume (RVSV) determined by segmentation of the RV in the short-axis
cine stack from the LVSV as previously described inMRStandard method.
This method assumes that there is no regurgitation of other valves, and
therefore thismethodwas not tested in the secondaryMR cohort due to
the regular presence of tricuspid regurgitation.
3. MRMVAV (4D flow mitral forward flow - 4D flow aortic SV)
This method used previously described retrospective valve tracking
to quantify mitral and aortic forward flows. Comprehensive retrospec-
tive valve tracking procedures are detailed in the online supplementary
document.
4. MRJet (4D flow direct jet assessment)
MR jets were directly quantified from the 4D flow dataset. Firstly
the jet was identified in multiple cine views including two-chamber,
three-chamber and four-chamber views. In the four-chamber view, a
reformatted plane was placed perpendicular to the regurgitant
jet within the left atrium for all phases of the jet life cycle. This
was done 1 cm above the mitral valve leaflets for consistency.
Dynamic regurgitant jets were quantified by adjusting the reformatted
plane throughout the lifecycle of the jet so that the reconstruction
remained perpendicular to the direction of flow. If multiple jets existed,
each jet was independently segmented and quantified. The total MR
volume was calculated as the sum of all MR jets.
2.11. Reproducibility tests
Intraobserver tests were performed by two investigators: BF (super-
vised by AS; >6 years CMR experience) and PG (>6 years CMR experi-
ence). Interobserver tests were done by two-second observers NB
(supervised by RvdG; >6 years CMR experience) and JMZ (supervised
by LZ; >6 years CMR experience). Intra-observer tests were carried
out after 1-month of previous analysis. All observers were blinded to
the results of other observers.
2.12. Statistical analysis
Statistical analysis was performed with IBM SPSS Statistics
(version-25). All data were treated as parametric. Continuous variables
are expressed as mean ± SD. A repeated-measures ANOVA was
performed on demographic comparisons. Intermethod, intra/inter-
observer reliability metrics were calculated using concordance correla-
tion coefficient (CCC) analysis and Bland-Altman statistics. CCC
measurements of precision (Pearson correlation coefficient) and accu-
racy (bias correction factor) are detailed in the analysis. The variation
between cohorts was quantified with a two-tailed t-test. A p-value of
less than 0.05 was considered statistically significant.
Fig. 1. Description of the four CMRMR quantification methods investigated by this study and the intra-observer and intra-observer Bland-Altman analysis results. Characteristics of each
quantification method. Orange arrow: prolapse of anterior MV leaflet.




Characteristics of the 35 patients are in Table 1. The average age of
patients was 66 ± 11 years. Overall, 66% of patients were male, 50% in
the primaryMR group, 53.8% in theMVR group and 100% in the second-
ary MR group. Standard volumetric CMR results are detailed in the on-
line supplementary table 2.
3.2. Intermethod agreements
For primary MR, the MRStandard and MRMVAV had comparable
regurgitant volume (28.6±2.5ml vs 24.2±2.4ml, P>0.05). However,
MRLVRVwas significantly higher thanMRMVAV. (Fig. 2 Panel A). TheMRJet
method regurgitant volumewas significantly higher than theMRStandard
(P < 0.001) and MRMVAV (P < 0.001) with a regurgitant volume of
40.5 ± 4.3 ml.
For the MVR group, the MRStandard, MRLVRV and MRMVAV and MRJet
methods all had comparable regurgitant volume (−2.1 ± 1.6 ml vs
5.18 ± 1.3 ml vs 1.0 ± 0.3 ml vs 1.1 ± 0.1 ml respectively). No method
was significantly different from any other method. The MRStandard
method had a negative regurgitant volume when the aortic stroke vol-
ume was greater than the LVSV (Fig. 2 Panel B).
In the secondaryMR group, all methods had comparable regurgitant
volumes; however, the MRLVRV method was not assessed in secondary
MR cases. The MRStandard, MRMVAV, and MRJet methods had regurgitant
volumes of 14.6± 1.3ml, 14.7± 1.2ml and 13.9± 1.6ml, respectively.
Taking into account all the intra/inter-observer tests recording in the
study, MRStandard method of regurgitation volume quantification corre-
lated with all the other three methods (MRLVRV R = 0.88, P < 0.0001;
MRMVAV R = 0.90, P < 0.0001; MRJet R = 0.80, P < 0.0001). MRMVAV
demonstrated the best correlation with MRStandard for both intra−/
inter-observer tests (Fig. 2 Panel C).
3.3. Intraobserver agreement
Fig. 1 and online supplementary table 3 detail the results of
intraobserver agreements. Of all methods tested, the MRMVAV method
of regurgitation volume quantification showed the least bias
(−0.1 ml, p = 0.90), however, no method demonstrated a statistically
significant bias (−1.0 ml,−0.9 ml, and− 2.6 ml for MRStandard, MRLVRV
andMRJet analysis respectively). In contrast, CCCwas poor forMRStandard
and MRLVRV quantification methods (0.80 and 0.88 respectively). How-
ever, the MRMVAV method demonstrated excellent CCC (0.96) and the
MRJet method demonstrated good CCC (0.91).
3.4. Interobserver agreement
Table 2 and Fig. 5 detail the results of interobserver agreements. For
primary MR, MRstandard and MRMVAV did not demonstrate statistically
significant bias (2.9 ml vs 1.0 ml). For both methods, the CCC was sub-
stantial (0.95 and 0.96, respectively). TheMRLVRVmethod had a statisti-










Age 67 ± 11 68 ± 11 62 ± 11 0.97
Gender (% Male) 50% 53.8% 100% 0.03
Height (cm) 167 ± 8 167 ± 9 177 ± 6 0.04
Weight (kg) 75 ± 11 77 ± 11 93 ± 19 0.01
Diabetes Mellitus 1 2 1 0.87
Smoking 7 7 5 0.98
Atrial Fibrillation 3 2 0 0.26
Ischaemic Heart Disease 9
NYHA Class 2.4 ± 0.9 1.3 ± 0.6 1.7 ± 0.7 0.01
Fig. 2. Panel A. Inter-method comparison ofMR volume quantified for different types ofmitral regurgitation.Panel B.MRvolume quantification data distribution for 2 observers. Note the
negative MR volume (red arrows) quantified by the MRStandard and MRLVRV. Panel C. Scatter matrix of all intra/inter-observer tests. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
B. Fidock, G. Archer, N. Barker et al. International Journal of Cardiology xxx (xxxx) xxx
4
The MRJet method also had a statistically significant bias of −20.1 ml
(p= 0.02). This method had a CCC of 0.57 for primary MR. For primary
MR, theMRMVAVmethod had the least bias between observers, whereas
the MRJet method had the most significant bias. The MRMVAV method
had minimal bias, and this was less than the MRStandard method.
For secondary MR, MRStandard, MRMVAV and MRJet all demonstrated
non-significant bias (1.8 ml vs −2.4 ml vs −0.1 ml). MRLVRV was not
tested in this group. The CCC for all methods was weak, however,
MRStandard and MRMVAV demonstrated similar CCC. For secondary MR,
all methods of quantification were comparable, and none showed sig-
nificant interobserver bias.
For the MVR group, no method demonstrated significant interob-
server bias. MRMVAV and MRJet had a comparable bias of 0.2 ml
and− 0.2 ml, respectively. MRstandard and MRLVRV also had comparable
bias (1.1 ml vs−1.1 ml). In this group, MRStandard, MRLVRV, MRMVAV and
MRJet all had poor CCC values (0.68 vs 0.48 vs 0.80 vs 0.41). For MVR, all
quantification methods had a comparable interobserver bias.
4. Discussion
In this study, we comprehensively investigate the intermethod
agreement for MR quantification by CMR methods in different types of
MR - primary and secondaryMR, and in patients with MVR. In addition,
this study defines the reproducibility of each CMRmethod forMR quan-
tification. In primary MR cases, MRstandard, MRLVRV andMRMVAV demon-
strated agreement to each other. However, in MVR and secondary MR,
all methods demonstrated reasonable agreement. In both intra/
inter-observer tests, MRMVAV demonstrated the least bias and the best
concordance correlation suggesting that this is the most precise way
to quantify MR.
A previous study by Cawley et al. investigated the reproducibility of
MR quantification by CMR in 26 patients with mixed aetiology [15].
They used the MRStandard method to quantify the regurgitant volume
and demonstrated similar bias (bias = 0 ml, −18 ml to 17 ml) for
intraobserver tests. Śpiewak et al. have previously demonstrated that
the exclusion of papillary muscles and trabeculations from the blood
pool and the inclusion of them in the LVmass calculation can lead to sig-
nificantly lower MR volume than when papillary muscles and
trabeculations are included in the blood pool [16]. This discrepancy
again limits the clinical translation of both MRStandard and MRLVRV for
the quantification of MR between two sites using different methods to
LV segmentation.
The most established method of primary MR quantification by CMR
is MRStandard. In a prospective study, Myerson et al. demonstrated that
patients with MRStandard ≤ 55 ml had a very high chance of remaining
free of symptoms or surgery [3]. Similar findings were noted by Penicka
et al. in a study which recruited 258 patients with primary MR [17]. In
our study, the method which demonstrates the best association and
least difference to MRStandard was MRMVAV. Importantly, this method
had far better limits of agreement than MRStandard. The most plausible
explanation for this finding is that this method addresses the issue
with the MRStandard, which is mainly a higher degree of error due to
two acquisitions and multiple slice segmentation for LV stroke volume
assessment on short-axis cine stack. MRMVAV method takes advantage
of the very accurate transvalvular forward flow assessment using the
valve tracking method [18]. In addition, both mitral and aortic flows
are quantified for the same averaged cardiac cycles, hence further re-
ducing the chance of errors due to the heart rate variability and spatial
miss-alignment. For primary MR, direct quantification with the MRJet
method is susceptible to exaggerated regurgitant volume quantifica-
tion. We speculate that this is because of variability in defining the
plane to quantify the MR jet. Slight variations can result in overestima-
tion as the reconstructed plane can have circulating flow within the LA
in direction of the MR jet.
In patients with secondaryMR, 4D flow derivedMRJet demonstrated
the least bias when compared to other methods. There are several ex-
planations for this observation - firstly, in this study, patients with sec-
ondary MR only had mild MR, and hence the regurgitation volume was
low, and any relative error using theMRStandard or theMRMVAVmethods
will appear larger. Secondly, MRJet method is far less challenging in
functional MR cases, as most of them have a central MR jet, which is
easy to identify and follow through-out systole.
In patients with MVR, if there is a recurrence of MR, further assess-
ment by imaging is recommended [19]. However, these guidelines ac-
knowledge the fact that MR quantification remains challenging in
MVR. All methods described in this study were able to quantify MR in
patients with MVR. However, as the regurgitant volume was minimal,
we noted inconsistencies with the MRStandard which can again be ex-
plained by the inaccuracy of LV stroke volume assessment using stan-
dard short-axis cine stack for MR volumes less than 10 ml. Both 4D
flow methods appear to be very reliable to quantify MR in this setting.
4.1. Clinical perspective
This study demonstrates that the 4D flow CMR derivedMR quantifi-
cation using theMRMVAV method is superior to other CMRmethods. 4D
flow CMRhas advantages over othermethods as it is one single acquisi-
tion capturing intra-cardiac flow information for the same cardiac cy-
cles. This inherent advantage improves the precision of flow
quantification and is not possible by any other non-invasive imaging
modality. Moreover, the same 4D flow dataset can be used to quantify
MR by twomethods -MRJet andMRMVAV. With the advent of fast accel-
eration 4D flow acquisition methods, it now possible to acquire the
cross-sectional flow data in 5–10 min. This can be easily adapted in
routine CMR protocols after gadolinium injection whilst waiting to do
late-enhancement imaging [20]. Quantification of primary MR remains
inherently very challenging as the MR jet can be very eccentric. Even
though direct MRJet quantification is possible with 4D flow, it is very
time consuming and as this study demonstrates it has poor reproduc-
ibility. This is mainly because it requires planning the MR jet plane for
every phase of left ventricular systolic acquisition, and then segmenting
the mitral regurgitation in the reconstructed plane; both of which, in-
crease the chance of variability between two assessors. Also, in cases
where there are multiple dynamic jets, it remains challenging to define
Table 2
Inter-observer reproducibility tests results.
Mean Bias Lower Limit Upper Limit P-value
Primary MR MRStandard 2.9 −7.0 12.8 0.07
MRLVRV 7.5 −10.7 25.7 0.02
MRMVAV 1.0 −8.0 10.0 0.46
MRJet −20.1 −71.9 31.7 0.02
MVR MRStandard 1.1 −16.4 18.6 0.66
MRLVRV −1.1 −20.9 18.7 0.70
MRMVAV 0.2 −2.7 3.0 0.72
MRJet −0.2 −1.7 1.4 0.43
Secondary MR MRStandard 1.8 −6.3 9.8 0.21
MRLVRV
MRMVAV −2.4 −9.4 4.5 0.06
MRJet −0.1 −17.8 17.6 0.97
CCC ρ (Precision) Cb (accuracy) P-value
Primary MR MRStandard 0.95 0.96 0.99 <0.01
MRLVRV 0.84 0.93 0.90 <0.01
MRMVAV 0.96 0.96 0.99 <0.01
MRJet 0.57 0.82 0.69 <0.01
MVR MRStandard 0.68 0.72 0.95 <0.01
MRLVRV 0.48 0.51 0.95 0.07
MRMVAV 0.80 0.85 0.95 <0.01
MRJet 0.41 0.43 0.5 0.14
Secondary MR MRStandard 0.85 0.87 0.97 <0.01
MRLVRV
MRMVAV 0.86 0.92 0.94 <0.01
MRJet 0.60 0.81 0.74 <0.01
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the appropriate VENC for MR jet assessment even before acquisition.
Hence, MRMVAV method should be the preferred method for improving
the precision and reliability for MR quantification. Future studies are
needed to evaluate the clinical outcome benefit of using the MRMVAV
method for MR quantification.
This study had some limitations. Firstly, direct comparison with
echocardiography was not possible as echocardiography did not record
MR volume. Secondly, the 4D flow acquisition was without respiratory
navigation which may have had an impact on the accuracy of derived
velocity/flow parameters. However, studies that carried out a head-to-
head comparison of whole-heart 4D flow CMR have demonstrated
that for quantification of intra-cardiac flow, both respiratory navigated
and non-respiratory navigated 4D flow CMR acquisitions are compara-
ble [21]. Another limitation that could influence the quality of the veloc-
ity profile is a low temporal resolution (40 ms).
5. Conclusion
CMR methods of MR quantification demonstrate agreement in sec-
ondary MR and MVR. In primary MR, this was not observed. Across all
types of MR, MRMVAV quantification demonstrated the highest repro-
ducibility and consistency.
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